A roundtable discussion of aromatase inhibitors as therapy for breast cancer

The Breast Journal
D Craig AllredEleftherios P Mamounas

Abstract

This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer. The new generation of aromatase inhibitors (anastrozole, letrozole, exemestane) have largely replaced megestrol acetate as a second-line therapy in postmenopausal women with hormone-responsive advanced breast cancer. In addition, anastrozole and letrozole have been shown to be superior to tamoxifen for first-line therapy. Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease.

References

Jan 1, 1987·British Journal of Cancer·M R WilliamsR W Blamey
Dec 1, 1993·Pharmacology & Therapeutics·A M Brodie
Mar 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W JonatM Azab
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P DombernowskyP F Trunet
Aug 26, 1998·The Journal of Steroid Biochemistry and Molecular Biology·A M Brodie, V C Njar
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M HarveyD C Allred
Jun 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Hamilton, M Piccart
Mar 24, 2000·Endocrine-related Cancer·J M DixonR C Leonard
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P E LønningG Massimini
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C K OsborneS A Fuqua
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BonneterreM von Euler
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzM von Euler
Nov 23, 2000·Cancer Control : Journal of the Moffitt Cancer Center·M J Ellis
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W F AndersonL A Brinton
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BuzdarC Brady
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen GeislerPer Eystein Lønning
Feb 19, 2002·The Journal of Steroid Biochemistry and Molecular Biology·W R Miller, J M Dixon

❮ Previous
Next ❯

Citations

Oct 14, 2006·Breast Cancer Research and Treatment·William R MillerMark Verrill
Mar 5, 2004·Expert Opinion on Pharmacotherapy·J Michael Dixon
Jun 28, 2007·Expert Opinion on Investigational Drugs·Paolo CarliniGianluigi Ferretti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Journal of Steroid Biochemistry and Molecular Biology
James N Ingle, Vera J Suman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Keitaro MatsuoHiroshi Ueoka
© 2022 Meta ULC. All rights reserved